A Phase I Study of BCA101, Alone and Combined with Pembrolizumab Immunotherapy, in People with Advanced Lung Cancer

Full Title

First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors

Purpose

The purpose of this study is to find the highest dose of the investigational drug BCA101 that can be given safely alone and in combination with the immunotherapy drug pembrolizumab in patients with advanced lung cancer that cannot be cured with standard treatments. BCA101 is an antibody that targets two proteins involved in cancer growth called EGFR and TGF-beta. By blocking these proteins, BCA101 may interfere with the signals that spur cancer growth. 

Pembrolizumab works by boosting the ability of the immune system to detect and kill cancer cells. Both BCA101 and pembrolizumab are given intravenously (by vein).